Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LIV by WellNow vs NuuVim

LIV by WellNow
Graded #262

Lower grade

vs+5.300000000000004
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 62.9/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +37
51
88
Dose & formulationNuuVim +23
73
96
Clinical oversightLIV by WellNow +37
79
42
Labs & monitoringLIV by WellNow +2
52
50
FulfillmentLIV by WellNow +2
63
61
Contract termsLIV by WellNow +8
55
47
LIV by WellNow · left barNuuVim · right bar

The numbers

MetricLIV by WellNowNuuVim
WeighScore62.9/10068.2/100
GradeCC
Scorecard rank#262#153
Semaglutide$279/mo$79/mo (all doses, 3-mo plan, new patients only, compounded)
TirzepatideNot disclosed$133/mo (all doses, 3-mo plan, new patients only, compounded)
Coverage5 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
LIV by WellNow

Graded #262 · C

Strengths

  • Flat $279/month covers medication, supplies, and unlimited virtual visits
  • Backed by established WellNow Urgent Care brand
  • Board-certified online medical providers
  • Same-day approval and monthly home delivery
  • Transparent all-inclusive pricing with no hidden fees

Where it loses points

  • Compounded semaglutide is not FDA-approved or evaluated
  • Only available in five states (IL, IN, MI, NY, PA)
  • No tirzepatide option offered
  • Insurance not accepted for compounded semaglutide
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard